Xaira Therapeutics Expands Leadership Team and Moves to New Headquarters
Xaira Therapeutics, an integrated biotechnology company focused on leveraging AI to transform drug discovery and development, announced two key appointments …
News
Relation Therapeutics Partners with GSK to Develop Treatments for Fibrotic Diseases and Osteoarthritis
Relation Therapeutics announced two strategic collaborations with GSK aimed at advancing drug discovery for fibrotic diseases and osteoarthritis, debilitating conditions …
Owkin Shares Federated Learning Tool for Secure RNA-Seq Analysis
Owkin has released FedPyDESeq2, a federated learning tool for differential expression analysis (DEA) in bulk RNA sequencing (RNA-seq). Designed to …
Citryll Secures €85M to Advance Monoclonal Antibody Targeting NETs in Inflammatory Diseases
Citryll, a biotechnology company focused on developing monoclonal antibody therapies to address immune-mediated inflammatory diseases, has completed an €85 million …
Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio with $75 Million Financing
Chroma Medicine and Nvelop Therapeutics have announced their merger to form nChroma Bio, a new biotechnology company focused on advancing …
DASA Launches Microbial Forensics Competition to Enhance UK Biosecurity
The Defence and Security Accelerator (DASA), in partnership with the Defence Science and Technology Laboratory (Dstl), has launched a new …
Tasca Therapeutics Launches with $52 Million to Advance Precision Oncology
Tasca Therapeutics, a biotechnology company focused on small molecule inhibitors for oncology, has raised $52 million in Series A financing. …
Dot Compliance Expands AI Capabilities to Transform Quality and Compliance in Life Sciences
Dot Compliance, a provider of AI-powered compliance and electronic quality management system (eQMS) solutions, has introduced the third generation of …
Cradle Achieves 8x Improved EGFR Binding Over Merck’s Cetuximab in Protein Design Challenge
Cradle’s platform has achieved first place in Adaptyv Bio's protein design competition by producing a novel EGFR-binding protein with a …
AQEMIA Reaches $100 Million in Funding, Plans Expansion and Prepares for Clinical Trials
AQEMIA, a techbio company teaching atomic scale physics to a generative AI, has announced reaching $100 million in cumulative funding. …
Recursion Reports Encouraging Interim Phase 1 Data a Selective CDK7 Inhibitor
Recursion (Nasdaq: RXRX) announced interim findings from the ongoing Phase 1/2 ELUCIDATE trial evaluating REC-617, a precision-designed, oral CDK7 inhibitor …
BioAge Labs Halts STRIDES Phase 2 Trial of Azelaprag-Tirzepatide Combo
BioAge Labs, which recently raised upwards of $198 million through an upsized IPO in September 2024 to fund its clinical …